Hepatocellular Carcinoma
Conditions
Brief summary
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
Interventions
DRUGLY2157299
LY2157299 administered orally
DRUGSorafenib
Sorafenib administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have histological evidence of a diagnosis of HCC (except HCC with fibrolamellar or mixed histology) not amenable to curative surgery. * Have Child-Pugh Class A. * Have the presence of measurable or evaluable lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. A measurable or evaluable lesion showing demonstrable progression after locoregional therapy could be also included. * Have not received sorafenib prior to enrollment. * Have resolution to Grade less than or equal 1 by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 of all clinically significant toxic effects of prior locoregional therapy, surgery, chemoembolization, systemic chemotherapy. * Have a performance status of less than or equal 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
Exclusion criteria
* Are currently enrolled, or discontinued within 28 days prior to enrollment from, a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Have undergone major surgery within 28 days prior to enrollment. * Have undergone hepatic locoregional therapy (including radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, cryoablation, percutaneous ethanol injection, or percutaneous microwave coagulation therapy) within 28 days prior to enrollment. * Have moderate or severe cardiac disease. * Myocardial infarction within 6 months prior to enrollment, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension. * Documented major electrocardiogram (ECG) abnormalities at the investigator's discretion within 28 days prior to enrollment. * Major abnormalities documented by echocardiography with Doppler at investigator's direction within 28 days prior to enrollment. * Have persistently elevated brain natriuretic peptide (BNP) or elevated troponin I within 14 days prior to enrollment. * Predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress. * Have a history of cardiac or aortic surgery. * Have undergone liver transplant. * Are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT) | Cycle 1 (28 days) |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (PK): Area Under the Plasma Concentration-time Curve (AUC) of LY2157299 | Cycle 1 Day1: predose through 6 hours post dose; Cycle1 Day14: predose through 24 hours post dose |
| PK: Maximum Observed Plasma Concentration (Cmax) of LY2157299 | Cycle 1 Day 1: Predose through 6 hours post dose; Cycle 1 Day 14: Predose through 24 hours post dose |
| Time to Progression (TTP) | Baseline to objective progressive disease (estimated as 6 months) |
| Progression-free Survival (PFS) | Baseline to objective progressive disease or death (estimated as 6 months) |
| The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD) | Baseline to objective progressive disease (estimated as 6 months) |
Countries
Japan
Outcome results
None listed